Business
Hemostemix at Invest Stuttgart
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix at Invest StuttgartCalgary, Alberta--(Newsfile Corp. - May 8, 2025) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands of investors, financial professionals, and innovators, offering a dynamic platform for Hemostemix to showcase its advancements and connect with potential ACP-01 clients and new shareholders.Hemostemix: A Leader in Autologous Stem Cell TherapyHemostemix stands at the forefront of regenerative medicine, specializing in autologous stem cell therapies. The flagship product, ACP-01, utilizes angiogenic cell precursors derived from a patient's own blood to treat a range of cardiovascular and conditions, including no-option:Peripheral Arterial Disease (PAD)Chronic Limb-Threatening Ischemia (CLTI)Ischemic CardiomyopathyNon-Ischemic Dilated CardiomyopathyCongestive Heart FailureAnginaVascular Dementia (Phase I)With over 498 patients treated and seven clinical studies completed, Hemostemix has demonstrated the safety, clinical relevancy and statistical efficacy across multiple indications. Innovative Financing: ACP-01 Therapy Convertible DebenturesTo support its growth and commercialization efforts, Hemostemix has introduced ACP-01 Therapy Convertible Debentures (TCDs). These instruments provide non-dilutive capital, largely, allowing the company to scale production and expand its clinical reach. Key features include:Conversion Options: Each TCD can be converted into an ACP-01 therapy or into Hemostemix Common Shares.Interest: 6% per annum, payable in shares.Transferability: TCDs are transferable, will-able, sale-able. As of early 2025, Hemostemix has sold over CAD $1.14 million of TCDs, facilitatingForecast of revenue.Scheduling of production.Scheduling of treatments.This approach supports operational scalability but also aligns production and treatments with patient demand, fostering sustainable growth.ConclusionHemostemix's participation in Invest Stuttgart 2025 underscores its commitment to advancing regenerative medicine, selling ACP-01 globally to no-option patients, and delivering shareholder value. By leveraging its pioneering therapies and innovative financin...